ArticleHepatology communications2026

Cost-effectiveness of HES V2.0 and GALAD for hepatocellular carcinoma surveillance in patients with cirrhosis.

Mert Sahinkoc et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.